Optometry and the drug enforcement administration

Area of Science:

• Optometry and Pharmaceutical Law
• Regulatory Agency Relations

Background:

• Optometric pharmaceutical privileges were established in 1971.
• The relationship between optometry and the Drug Enforcement Administration (DEA) remains undefined.
• This ambiguity impacts optometry's role in primary eye care.

Purpose of the Study:

• To clarify the Drug Enforcement Administration's (DEA) function.
• To advocate for a stronger collaborative relationship between optometry and the DEA.
• To support optometry's expansion as a primary vision and eye care provider.

Main Methods:

• Review of the Drug Enforcement Administration's (DEA) mandate and operations.
• Analysis of the current legal and professional standing of optometrists regarding pharmaceutical agents.
• Proposal for enhanced inter-agency collaboration.

Main Results:

• The Drug Enforcement Administration (DEA) plays a critical role in regulating pharmaceutical agents.
• Current optometric practice lacks a clearly defined operational framework with the DEA.
• A strengthened relationship is feasible and beneficial.

Conclusions:

• Optometry's scope of practice, particularly in primary eye care, is enhanced by a defined relationship with the DEA.
• Proactive engagement with the DEA is essential for the future of optometric services.
• Further development requires clear regulatory understanding and collaboration.